Results 41 to 50 of about 206,533 (287)

Alkaloids from the Sponge Stylissa carteri Present Prospective Scaffolds for the Inhibition of Human Immunodeficiency Virus 1 (HIV-1). [PDF]

, 2016
The sponge Stylissa carteri is known to produce a number of secondary metabolites displaying anti-fouling, anti-inflammatory, and anti-cancer activity. However, the anti-viral potential of metabolites produced by S.
Bader, Theresa Maria, Brack-Werner, Ruth, Gerwick, William H, Helfer, Markus, Kremb, Stephan, O'Rourke, Aubrie, Schmitt-Kopplin, Philippe, Voolstra, Christian R   +7 more
core   +2 more sources

HIV drug resistance prediction with weighted categorical kernel functions [PDF]

, 2019
Background: Antiretroviral drugs are a very effective therapy against HIV infection. However, the high mutation rate of HIV permits the emergence of variants that can be resistant to the drug treatment.
Belanche Muñoz, Luis Antonio, Pérez Enciso, Miguel, Ramon Gurrea, Elies   +2 more
core   +3 more sources

HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate

Viruses, 2010
HIV-1 reverse transcriptase (RT) inhibitors currently used in antiretroviral therapy can be divided into two classes: (i) nucleoside analog RT inhibitors (NRTIs), which compete with natural nucleoside substrates and act as terminators of proviral DNA ...
Giovanni Maga, Marco Radi, Marie-Aline Gerard, Maurizio Botta, Eric Ennifar   +4 more
doaj   +1 more source

Comparative Molecular Field Analysis (CoMFA) for Thiotetrazole Alkynylacetanilides, a Non-Nucleoside Inhibitor of HIV-1 Double Mutant K103N/Y181C Reverse Transcriptase

E-Journal of Chemistry, 2009
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are allosteric inhibitors of the HIV-1 reverse transcriptase. HIV-1 resistance to nucleoside RT inhibitors such as AZT can arise through mutations in the coding region of RT.
Sivan Sree Kanth, Kotla Sai Abhishake, Manga Vijjulatha   +2 more
doaj   +1 more source

Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies

Viruses, 2022
The enzyme reverse transcriptase (RT) plays a central role in the life cycle of human immunodeficiency virus (HIV), and RT has been an important drug target.
Abhimanyu K. Singh, Kalyan Das
doaj   +1 more source

Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study [PDF]

, 2017
Background. Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects of treatment. Methods.
Bernasconi, Enos, Cavassini, Matthias, Egger, Matthias, Elzi, Luigia, Furrer, Hansjakob, Hirschel, Bernard, Ledergerber, Bruno, Lehmann, Roger, Rickenbach, Martin, Schmid, Patrick, Weber, Rainer   +10 more
core  

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]

, 2020
BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.
Barnhart, Scott, Gilmore, Hailey J, Grignon, Jessica S, Hunt, Gillian, Liegler, Teri, Lippman, Sheri A, Mooney, Alyssa C, Prach, Lisa M, Puren, Adrian, Truong, Hong-Ha M   +9 more
core  

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]

, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry, Alexandra Calmy, Anne-Marie Taburet, Avihingsanon, Blackwelder, Boulle, Carlota Silva, Chen, Christine Rouzioux, Christophe Michon, Cohen, Cohen, Davies, Dejesus, Dieterich, Elisabeth Baudin, Elizabete Nunes, Flandre, Ford, Gengiah, Gulick, Ilesh Jani, Kwara, Laura Ciaffi, Maartens, Manosuthi, Manosuthi, Maryline Bonnet, Matteelli, Mbuagbaw, Meintjes, Nilesh Bhatt, Rui Bastos, Scourfield, Shipton, Soriano, Swaminathan, Tang, Telenti, van Leth   +39 more
core   +3 more sources